Experimental Ebola Drug Cured 100% of Monkeys Tested

August 30th, 2014

Via: USA Today:

In what scientists are calling a “monumental achievement,” an experimental medication called ZMapp — given on a compassionate basis to a handful of Ebola victims in the current outbreak — cured 100% of monkeys treated in a Canadian study, researchers announced Friday.

ZMapp, made by Mapp Biopharmaceuticals of San Diego, is in the early stage of development and has never been formally tested in humans. In a study published Friday in the journal Nature, however, the drug allowed all 18 rhesus macaques infected with a lethal dose of Ebola to recover. The drug worked even when given five days after infection. The monkeys received three doses of ZMapp, administered three days apart, according to the study, which was conducted by the Public Health Agency of Canada.

The three monkeys that did not receive ZMapp died within eight days of infection.

In monkeys given ZMapp, however, the drug reversed severe symptoms, including severe bleeding, rashes and elevated liver enzymes, a sign of liver failure. Three weeks after infection, tests showed the surviving animals had no detectable Ebola virus in their blood.

Posted in [???], Health | Top Of Page

4 Responses to “Experimental Ebola Drug Cured 100% of Monkeys Tested”

  1. mangrove says:

    The three monkeys that did not receive ZMapp died within eight days of infection.

    WHAT? They killed see no evil, hear no evil, and speak no evil?

    I’ll most definitely get in line for the ZM (ZoMbie) app (apocalypse application).

    Give it to me! (On a compassionate basis, please.)

  2. djc says:

    Ha, more crap peddled by big Pharma & their acolytes in the press, check this out

    http://www.naturalnews.com/046669_Ebola_ZMapp_experimental_drug.html

  3. Dennis says:

    What I don’t understand is why it was given on a ‘compassionate basis’ to only a handful of people when so many have died in Africa.

    Maybe they didn’t have enough to go around.

Leave a Reply

You must be logged in to post a comment.